Establishment of an effective therapy for TNBCs due to the restricted therapeutic strategies relative to the lack of expression of ER/PR/HER2 and intrinsic or developed resistance still remains as a great challenge in breast cancer therapy. Here, ESR1 is linked to breast carcinoma.